BridgeBio Pharma Prices $550 Million Convertible Notes Offering
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 16 2026
0mins
Source: NASDAQ.COM
- Financing Size: BridgeBio Pharma announced a $550 million offering of 0.75% convertible senior notes, expected to close on January 21, 2026, indicating an active financing strategy in the capital markets.
- Additional Option: The company granted initial purchasers an option to buy an additional $82.5 million in notes, enhancing financing flexibility and potentially supporting future capital needs.
- Use of Net Proceeds: The estimated net proceeds of approximately $538.4 million will be used to repurchase a portion of the 2.50% convertible senior notes due 2027 and for general corporate purposes, reflecting the company's focus on debt management.
- Stock Buyback Plan: BridgeBio intends to use about $82.5 million in cash to repurchase approximately 1.1 million shares of common stock, aimed at enhancing shareholder value and optimizing capital structure, demonstrating confidence in its stock.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like BBIO with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on BBIO
Wall Street analysts forecast BBIO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BBIO is 87.63 USD with a low forecast of 69.00 USD and a high forecast of 100.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
17 Analyst Rating
17 Buy
0 Hold
0 Sell
Strong Buy
Current: 79.100
Low
69.00
Averages
87.63
High
100.00
Current: 79.100
Low
69.00
Averages
87.63
High
100.00
About BBIO
BridgeBio Pharma, Inc. is a biopharmaceutical company. It discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases. Its pipeline of development programs ranges from early science to advanced clinical trials, which includes Attruby, an oral small molecule near-complete transthyretin (TTR) stabilizer, for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); Beyonttra for the treatment of TTR Amyloidosis; Low-dose Infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor (TKI) for the treatment of children with achondroplasia and hypochondroplasia; Encaleret, an oral small molecule antagonist of the calcium sensing receptor (CaSR) that it is developing for the treatment of Autosomal Dominant Hypocalcemia Type 1 (ADH1), and BBP-418, for the treatment of Limb Girdle Muscular Dystrophy Type 2I. It also conducting a Phase 1/2 study (CANaspire) for BBP-812 for Canavan disease.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
NASDAQ 100 Pre-Market Indicator Rises 126.58 to 25,673.66
- Active Stocks: ImmunityBio, Inc. (IBRX) rises by 0.5199 to $4.47 in pre-market trading with a volume of 15,815,869 shares, indicating investor confidence in its future performance.
- Strong ETF Performance: ProShares UltraPro QQQ (TQQQ) increases by 0.6799 to $55.06 with 3,426,778 shares traded, reflecting a 214.63% rise from its 52-week low, showcasing strong demand for tech stocks.
- Individual Stock Outlook: Micron Technology, Inc. (MU) climbs 16.9056 to $353.54 with a volume of 1,816,774 shares, with an expected EPS of $8.18 for the fiscal quarter ending February 2026, indicating improved earnings forecasts.
- Analyst Rating Insights: AT&T Inc. (T) declines by 0.0516 to $23.68 with 2,123,037 shares traded, and Zacks reports its current mean recommendation is in the 'buy range', suggesting analysts are optimistic about its future performance.
Continue Reading
BridgeBio Pharma Prices $550M Convertible Notes Offering with $538.4M Net Proceeds Expected
- Offering Size: BridgeBio Pharma has successfully priced a $550M offering of 0.75% convertible senior notes, expected to close on January 21, 2026, indicating strong demand in the capital markets.
- Conversion Terms: Each $1,000 note can be converted into 9.0435 common shares at a conversion price of approximately $110.58, representing a 45% premium over the last closing price of $76.26 on January 15, 2026, providing an attractive option for investors.
- Use of Proceeds: The company plans to utilize approximately $538.4M in net proceeds to repurchase or repay part of its 2.50% convertible notes due 2027, as well as for general corporate purposes including working capital and capital expenditures, enhancing financial flexibility.
- Market Strategy: While targeting over 30% market share for Attruby, BridgeBio Pharma continues to advance its late-stage pipeline, demonstrating ongoing growth potential in the biopharmaceutical sector.
Continue Reading